KR
38
-2
GRMN
68
-2
STT
60
7
C
50
-4
SLG
62
3
THC
62
2
BXP
47
3
VLO
33
4
JWN
52
2
INTC
41
5
HRB
54
2
AMG
22
-16
DFS
56
-4
LB
30
-8
PYPL
41
2
HPQ
52
3
HCP
47
-9
KHC
22
-3
ROK
38
-14
CHD
42
-3
KR
38
-2
GRMN
68
-2
STT
60
7
C
50
-4
SLG
62
3
THC
62
2
BXP
47
3
VLO
33
4
JWN
52
2
INTC
41
5
HRB
54
2
AMG
22
-16
DFS
56
-4
LB
30
-8
PYPL
41
2
HPQ
52
3
HCP
47
-9
KHC
22
-3
ROK
38
-14
CHD
42
-3
Financhill
Back

Cara Therapeutics Quote, Financials, Valuation and Earnings

Write This Down: Tuesday at 2 p.m. ET!

Don't Miss Our LIVE Trade
Sell
39

CARA
Cara Therapeutics

Last Price:
0.29
Seasonality Move:
5.28%

7 Day Trial

ALL ACCESS PASS

$ 7

The Mysterious VC Firm Behind Nvidia's Secret Weapon

Details Here!

Cara Therapeutics Price Quote

$0.29
0.00 (-0.17%)
(Updated: November 5, 2024 at 2:35 PM ET)

Cara Therapeutics Key Stats

Sell
39
Cara Therapeutics (CARA) is a Sell
Day range:
$0.28 - $0.30
52-week range:
$0.24 - $1.40
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
1.44
P/B ratio:
1.37%
Volume:
285.7K
Avg. volume:
404.3K
1-year change:
-78.48%
Market cap:
$15.9M
Revenue:
$21M
EPS:
$-2.04

How Much Does Cara Therapeutics Make?

Is Cara Therapeutics Growing As A Company?

  • What Is Cara Therapeutics's Growth Rate Quarterly?
    Quarterly YoY revenue growth is -0.86%
  • What Is Cara Therapeutics's EPS Quarterly YoY Growth Rate?
    Quarterly, year-over-year diluted EPS growth rate is 0%

Cara Therapeutics Stock Price Performance

What Is Cara Therapeutics 52-Week High & Low?

Cara Therapeutics Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Cara Therapeutics?

  • How Much Debt Does Cara Therapeutics Have?
    Total long term debt quarterly is $0
  • How Much Cash Does Cara Therapeutics Have?
    Cash and short term investments quarterly total is $56.6M
  • What Is Cara Therapeutics’s Book Value Per Share?
    Book value per share is 0.21

Is Cara Therapeutics Cash Flow Positive?

  • What Is CARA Cash Flow From Operations?
    Cash flow from operations (TTM) is -$79.9M
  • What Is Cara Therapeutics’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $36.3M
  • What Is Cara Therapeutics’s Cash Flow From Investing?
    Cash flow from investing (TTM) is $34.2M

Cara Therapeutics Return On Invested Capital

  • Is Management Doing A Good Job?
    CARA return on invested capital is -189.52%
  • What Is Cara Therapeutics Return On Assets?
    ROA measures how assets are converting to revenues and is -103.2%
  • What Is CARA Return On Equity?
    ROE is a measure of profitability and is -189.52%

Cara Therapeutics Earnings Date & Stock Price

Cara Therapeutics Competitors

  • Who Are Cara Therapeutics's Competitors?
    Below is a list of companies who compete with Cara Therapeutics or are related in some way:
    • Perspective Therapeutics Inc (CATX)
    • Cocrystal Pharma Inc (COCP)
    • Citius Pharmaceuticals Inc (CTXR)
    • Oragenics Inc (OGEN)
    • Alaunos Therapeutics Inc (TCRT)

Cara Therapeutics Dividend Yield

Cara Therapeutics Analyst Estimates

YoY Growth Past Surprise
EPS: 0% -33%
Revenue: -85.71% -15.56%

Analyst Recommendations

Buy Recommendations: 0
Hold Recommendations: 4
Sell Recommendations: 0
Price Target: 1.66
Upside from Last Price: 469.71%

Major Shareholders

  • How many CARA shares are owned by institutional investors?
    29.1M CARA shares are owned by institutional investors
  • How many CARA shares are owned by insiders?
    3.1M CARA shares are owned by insiders